Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Immunotherapy, asthma

Patients who may benefit from allergen immunotherapy include those who do not tolerate traditional drug therapy (e.g., nosebleeds with intranasal steroids or sedation with antihistamines), suffer from severe symptoms, have comorbid conditions (e.g., asthma or sinusitis), fail drug therapy, or prefer not to take long-term medication. [Pg.925]

Janssen EM, van Oosterhout AJM, Nijkamp FP, van Eden W, Wauben MHM The efficacy of immunotherapy in an experimental murine model of allergic asthma is related to the strength and site of T cell activation during immunotherapy. J Immunol 2000 165 7207-7214. [Pg.47]

Bousquet J, Lockey R, Mailing HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, et al Allergen immunotherapy therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. [Pg.173]

Bousquet J, Hejjaoui A, Michel EB. Specific immunotherapy in asthma. J Allergy Clin Immunol 1990 86 292-305. [Pg.655]

Passalacqua G. 2007. Allergic rhinitis and its impact on asthma update. Allergen immunotherapy. [Pg.146]

Specific immunotherapy using subcutaneous injections (SCIT) has been used for almost 100 years. It is clearly helpful for allergic rhinitis from pollens. Treatment of asthma, especially from molds, is not as clearly successful. Factors such as the inconvenience and expense of traveling for allergy shots contribute to a dropout rate greater than 50% over a multiyear course of... [Pg.1]

The World Health Organization position paper [31] published in 1998 found that properly conducted double-blind, placebo-controlled trials have shown the effectiveness of sublingual-swallow immunotherapy with grass, Parietaria and mite vaccines. The ARIA (Allergic Rhinitis and Impact on Asthma) [32] guidelines published in 2001 gave specific indications for usage. [Pg.8]

Donahue JG, Greineder DK, Connor-Lacke L, Canning CF, Platt R Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol 1999 82 339-347. [Pg.8]

Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, Pauli G, Caillaud D, Dubost R, Leynadier F, Vervloet D, Herman D, Galvain S, Andre C Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites A double blind placebo-controlled study. Allergy 1999 54/3 249-260. [Pg.8]

Mungan D, Misirligil Z, Gurbuz L, et al Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma - A placebo controlled study. Ann Allergy Asthma Immunol 1999 82 485 190. [Pg.8]

Tari MG, Mancino M, Monti G Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite - A double blind study. Allergol Immunopathol 1990 18/5 277-284. [Pg.8]

Bahceciler NN, Isik U, Bartan IB, Basaran MM Efficacy of sublingual immunotherapy in children with asthma and rhinitis A double blind, placebo-controlled study. Pediatr Pulmonol 2001 32 49-55. [Pg.8]

Van Deusen MA, Angelini B, Cordoro KM, Seiler BA, Wood L, Skoner DP Efficacy and safety of oral immunotherapy with short ragweed extract. Ann Allergy Asthma Immunol 1997 78 573-580. [Pg.9]

Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C, Papageorgiou PS Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998 53 662-672. [Pg.9]

Abramson MJ, Puy RM, Weiner JM Is allergen immunotherapy effective in asthma A metaanalysis of randomized controlled trials. Am J Respir Crit Care Med 1995 151 969-974. [Pg.41]

Leng X, Fu YX, Ye ST, Duan SQ A double blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to pollen allergen and serum specific IgE antibodies. Ann Allergy 1990 64 27-31. [Pg.42]

Purrello-D Ambrosio F, Gangemi S, Isola S, La Motta N, Puccinelli P, Parmiani S, Savi E, Ricciardi L Sublingual immunotherapy A double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy 1999 29 968-973. [Pg.43]

Hirsch T, Sahn M, Leupold W Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997 8 21-27. Bahceciler NN, Isik U, Barlan IB, Basaran MM Efficacy of sublingual immunotherapy in children with asthma and rhinitis A double-blind, placebo-controlled study. Pediatr Pulmonol... [Pg.61]

Ross RN, Nelson HS, Finegold I Effectiveness of specific immunotherapy in the treatment of asthma A meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther 2000 22 329-341. [Pg.61]

Sublingual immunotherapy House dust mite Desensitization Asthma Rhinitis... [Pg.62]


See other pages where Immunotherapy, asthma is mentioned: [Pg.36]    [Pg.201]    [Pg.45]    [Pg.84]    [Pg.156]    [Pg.186]    [Pg.652]    [Pg.652]    [Pg.122]    [Pg.1863]    [Pg.121]    [Pg.220]    [Pg.1]    [Pg.2]    [Pg.9]    [Pg.51]    [Pg.53]    [Pg.63]    [Pg.74]    [Pg.77]    [Pg.77]   
See also in sourсe #XX -- [ Pg.637 ]




SEARCH



Asthma specific immunotherapy

Immunotherapy

© 2024 chempedia.info